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Abstract
Background: An exaggerated inflammatory response occurs in the first few days of life in infants
who subsequently develop bronchopulmonary dysplasia (BPD). The increase of inflammatory
cytokines in many disease processes is generally balanced by a rise in anti-inflammatory cytokines.
Interleukin-4 (IL-4) and interleukin-13 (IL-13) have been shown to inhibit production of several
inflammatory cytokines important in the development of BPD.
Methods: We sought to determine if a correlation exists between the presence or absence of IL-
4 and IL-13 in tracheal aspirates (TA) during the first 3 weeks of life and the development of BPD
in premature infants. Serial TAs were prospectively obtained from 36 very low birth weight infants
and IL-4 and IL-13 concentrations were determined by ELISA.
Results: Infants who developed BPD (n = 19) were less mature (25.3 ± 0.02 wks vs. 27.8 ± 0.05
wks; p < 0.001), and had lower birth weights (739 ± 27 g vs.1052 ± 41 g; p < 0.001). IL-4 and IL-13
were detectable in only 27 of 132 and 9 of 132 samples assayed respectively. Furthermore, the
levels detected for IL-4 and IL-13 were very low and did not correlate with the development of
BPD.
Conclusions: TA concentrations of IL-4 and IL-13 do not increase significantly during acute lung
injury in premature infants.
Background
An exaggerated inflammatory response occurs in the first
few days of life in infants who subsequently develop bron-
chopulmonary dysplasia (BPD). This response includes
an increase in airway protein, inflammatory cells and
cytokines [1–7]. Increased concentrations of inflamma-
tory cytokines such as interleukin-1β (IL-1β), interleukin-
6 (IL-6), macrophage inflammatory protein 1α (MIP-1α),
tumor necrosis factor-α (TNFα) and interleukin-8 (IL-8)
have been found in the tracheal aspirates (TA) of infants
who developed BPD [3–8]. Additionally, the magnitude
of the inflammatory response seems to correlate with the
infant's ability to recover fully from acute lung injury that
occurs with hyaline membrane disease.
Inflammatory responses may be modulated by several
anti-inflammatory or otherwise immunomodulatory
cytokines. The role of these cytokines in the pulmonary
inflammatory response of the preterm newborn with hya-
line membrane disease or its progression to BPD has had
little study. Interleukin-10, which inhibits cytokine pro-
duction from activated macrophages, is undetectable or
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preterm infants during the first 3 days of life [9]. These
observations suggest an absence of immunomodulatory
cytokines, particularly those that down regulate inflam-
mation in the premature infant's lung, may play a role in
the development of BPD.
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are struc-
turally related cytokines that share similar properties and
receptor components [10]. The actions of these cytokines
are pleiotropic, some may be beneficial in moderating
lung inflammation, and others may be detrimental. For
example, IL-4 and IL-13 have both been shown to inhibit
production of several inflammatory cytokines that may be
important in the development of BPD in vivo and in vitro
[11–18]. However, increased IL-4 and IL-13 expression
and production is associated with the development of
bronchial hyperreactivity and asthma, which are signifi-
cant long term complications of BPD [19,20].
Since information on the possible role of IL-4 and IL-13
in the pathogenesis of BPD is unknown, we designed a
study to determine the role of these cytokines in the devel-
opment of BPD. Specifically, we prospectively determined
tracheal aspirate concentrations of IL-4 and IL-13 during
the first 3 weeks of life in mechanically ventilated very low
birth weight infants who did and did not develop BPD.
Our goal was to determine if a correlation exists between
the presence or absence of these cytokines in tracheal aspi-
rates and the development of BPD in premature infants.
Methods
The study population consisted of very low birth weight
infants admitted to the neonatal intensive care unit
(NICU) at the Louisiana State University Health Sciences
Center in Shreveport. Patients were admitted to the NICU
between February 1997 and March 1998. Eligibility crite-
ria included: a birth weight of less than 1500 grams,
mechanical ventilation (MV) during the first day of life,
and informed consent. Infants who were not expected to
survive for 24 hours and those with major respiratory, car-
diovascular or neurological anomalies were excluded. The
study was approved by the Institutional Review Board for
Human Research at LSUHSC.
Tracheal aspirates were collected when clinically indi-
cated. Sterile normal saline (0.5 ml) was instilled into the
endotracheal tube and 3–4 manual breaths were provided
using a self inflating bag. Airway secretions were aspirated
into sterile traps and any material remaining in the cathe-
ter was washed into the trap with an additional 0.5 cc
saline. Serial aspirates were obtained at 0–24 hours, 48–
72 hours, 4–5 days, 7–9 days, 12–14 days and on day 21
if the infant remained on mechanical ventilation. Routine
bacterial and genital mycoplasma cultures were per-
formed on tracheal aspirates collected in the first 24
hours. All TAs were frozen at -20°C until assayed for
cytokines by enzyme linked immunoassay (ELISA).
Clinical management of the infants was directed by the
attending neonatologists. The use and timing of steroids
and indomethacin prophylaxis were not specified by the
protocol. Demographic data collected in this study
included; the need for surfactant therapy, duration of MV,
use of corticosteroids, incidence of patent ductus arterio-
sus (PDA), use of indomethacin (prophylactic and thera-
peutic), presence and severity of intraventricular
hemorrhage (IVH), and the presence of periventricular
leukomalacia (PVL). Maternal data included mode of
delivery, complications of pregnancy, the use of antenatal
steroids and antibiotics.
Several definitions of BPD have been used through the
years. Initially BPD was defined as oxygen dependency at
28 days of age [21,22]. More recently, the use of oxygen
dependency at 36 weeks PCA has been proposed as a
more suitable definition of BPD [23]. Both of these defi-
nitions however, predict long term respiratory abnormal-
ities [24]. More recently a NIH consensus has proposed
new definitions and diagnostic criteria that provide grada-
tion of BPD into mild, moderate and severe forms [25].
Since even mild BPD may presage chronic respiratory
problems we used the earlier broader definition of BPD
(defined as oxygen dependency at 28 days postnatal age
and a chest radiograph showing changes compatible with
BPD) [24,21].
ELISA
The recombinant human cytokines IL-4 and IL-13, mono-
clonal and biotinylated monoclonal antibodies to IL-4
and IL-13 were purchased from Endogen (Woburn, MA).
Streptavidin-horseradish peroxidase (Strep-HRP) conju-
gate was purchased from Pharmingen (San Diego, CA).
Poly horseradish peroxidase-streptavidin (PolyHRP-
Strep) and dilution buffer were obtained from Endogen.
Horseradish peroxidase-conjugated rabbit anti-goat anti-
body, monoclonal and polyclonal goat anti-human secre-
tory component antibodies, bovine serum albumin
(BSA), and oxalic acid were purchased from Sigma Chem-
ical Co (St. Louis, MO). Human secretory IgA was pur-
chased from ICN Pharmaceuticals (Costa Mesa, CA).
ELISA plates were obtained from Costar (Cambridge,
MA). 2,2'-azino-di [3-ethyl-benzthiazoline-6-sulphonic
acid] (ATBS) and 3, 3', 5, 5'-tetramethylbenzidine (TMB)
peroxidase substrate kits were purchased from Bio-RAD
(Hercules, CA).
Concentrations of coating and detecting antibodies were
titrated to optimize assay conditions. The ELISAs were val-
idated in TAs by adding 1000 pg of recombinant cytokinePage 2 of 8
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centrations and comparing measured cytokine concentra-
tions with what was added. Recovery was >80% of added
cytokines. The R-squared values of the standard curves for
these assays were generally greater than 0.95 with most
assays having R-squared value of 0.99. Assays with stand-
ard curves with R-squared values less than 0.9 were
repeated.
ELISA plates for IL-4 and IL-13 assays were coated with
100 µl of the appropriate monoclonal antibody in PBS
(pH 7.4) overnight at 4°C. The coating antibodies were
used at the following concentrations: IL-4, 3.4 µg/ml; IL-
13, 3.8 µg/ml; and secretory component, 2.0 µg/ml. After
coating, the ELISA plates were washed 3 times (5 minutes
per wash) with 200 µl of phosphate buffered saline (PBS)
containing 0.05% Tween 20 (wash buffer). All subsequent
washes were performed similarly. The plates were then
blocked using 200 µl PBS – Tween 20 containing 3% (w/
v) BSA (blocking buffer) overnight at 4°C. After blocking,
the plates were washed 3 times in wash buffer prior to use.
All subsequent steps were performed in blocking buffer.
Tracheal aspirates and recombinant cytokine standards
were diluted in blocking buffer.
For the IL-4 ELISA, 50 µl TA (diluted 1:1 in blocking
buffer) or recombinant cytokine standards (7.8–1000 pg/
ml) were incubated in antibody coated ELISA plates for 1
hour at room temperature. Without washing or removing
standards/samples (in accordance to manufacturers spec-
ifications), 50 µl biotinylated monoclonal anti-IL-4 anti-
body (500 ng/ml) was added and incubated for another 1
hour at room temperature. The plates were washed 4
times and then incubated with Strep-HRP (1:1000) for 30
minutes at room temperature. After washing 4 times, 100
ul TMB substrate was added to develop color. The reaction
was stopped by adding 100 µl of 0.2 N sulphuric acid and
the plates were read at 450 nm.
For the IL-13 ELISA, 50 µl TA (diluted 1:1 in blocking
buffer) or recombinant cytokine standards (3.9–1000 pg/
ml) were incubated in antibody coated ELISA plates for 1
hour at room temperature. Without washing or removing
standards/samples, 50 µl biotinylated monoclonal anti-
IL-13 antibody (500 ng/ml) was added and incubated for
another 1 hour at room temperature. The plates were
washed 4 times and then incubated with polyHRP-
streptavidin conjugate (1:7000 in dilution buffer) for 30
minutes at room temperature. After washing 4 times, the
plates were developed as described above.
The ELISAs for secretory component has been previously
described [26]. TA samples were diluted 1:400 to 1:6400
(in blocking buffer) for the secretory component assay.
Sensitivities of the assays were as follows: IL-4, 15 pg/ml;
IL-13, 3.9 pg/ml; secretory component; 3 ng/ml.
Data Analysis
To adjust for variation in collection of tracheal aspirates,
cytokine concentrations were normalized to secretory
component [27]. Statistical analysis was performed using
the SPSS for Windows version 6.0 (SPSS Inc., Chicago, IL).
Chi square analysis was used to assess the statistical differ-
ences in categorical variables. The Student t-test was used
to assess normally distributed variables. The duration of
mechanical ventilation, oxygen use and hospitalization
were not normally distributed therefore; the Wilcoxon
Rank Sum test was used for analysis of these factors. The
differences in TA cytokine concentrations were assessed
using ANOVA. Differences in IL-4 concentrations between
infants with and without BPD at each time point were also
assessed post hoc using Wilcoxon Rank Sum test (data not
normally distributed) without correction. A probability
value of less than 0.05 was considered statistically signifi-
cant. The data are presented as mean ± standard error of
the mean (SEM).
Results
Thirty six (36) patients were enrolled in the study, 19 (53
%) developed BPD. Of the 19 patients with BPD, 3 infants
met the criteria for severe BPD, the remainder were mild-
moderate [25]. Infants who developed BPD were smaller,
of lower gestational age, were more likely to have a tra-
cheal aspirate culture positive for Ureaplasma urealyticum
(Uu), and were more likely to have received treatment
with indomethacin or postnatal dexamethasone (Table
1). Ureaplasma urealyticum was isolated from tracheal aspi-
rate cultures in 8 (22%) study infants. Isolation of Uu
from the TA was associated with an increased incidence of
BPD (Table 1). There were three deaths among the study
patients. One infant died at 14 days of age from pulmo-
nary hemorrhage, Uu pneumonia and progressive respira-
tory failure. Two patients in the BPD group died, one of
respiratory failure as a result of Uu infection, pulmonary
hemorrhage and fungal sepsis at 43 days of age and
another at 49 days of age died of sepsis and multi-organ
failure.
IL-4 was detected in 17 of 89 (19.1%) samples from
infants who subsequently developed BPD and 10 of 43
(23.3%) samples from infants who did not develop BPD.
Raw concentrations of IL-4 ranged from undetectable
(<16 pg/ml) to 587 pg/ml. Figure 1A shows the TA con-
centrations of IL-4 normalized to secretory component for
all infants studied. When detected, TA concentrations of
IL-4 were uniformly very low (< 6 pg/µg secretory compo-
nent). TA IL-4 concentrations increased slightly over time
in infants who developed BPD but these differences were
not significant (Figure 1B). While TA IL-4 concentrationsPage 3 of 8
(page number not for citation purposes)
BMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/8were slightly higher in infants who developed BPD than
those infants who did not develop BPD, these differences
were also not significant (ANOVA and post hoc Wilcoxon
Rank Sum tests). Additionally, maximal TA concentra-
tions of IL-4 were not different between groups (0.17 ±
0.07 pg/µg secretory component vs 0.85 ± 0.45 pg/µg
secretory component, p = 0.183, control vs. BPD). Inter-
leukin-13 was detected in only 9 of 132 TA samples (data
not shown). There was no correlation between antenatal
or postnatal steroids, gestational age, birth weight or iso-
lation of Uu from tracheal secretions and concentrations
of IL-4 and IL-13 (data not shown). Additionally, there
were too few patients to analyze IL-4 concentrations in
patients with severe BPD.
Discussion
Inflammation is the primary pathological process that
precedes the development of BPD. Increased tracheal con-
centrations of inflammatory cytokines have been reported
in infants who develop this disease [3–8]. Interleukin-4
and IL-13 have been shown to modulate lung inflamma-
tion in animal models and thus the presence or absence of
these cytokines in the lung may be important determi-
nants in the pathogenesis of BPD [16,28].
Interleukin-4 is a pleiotropic cytokine produced predom-
inately by T-lymphocytes and alveolar macrophages
[10,29]. Interleukin-4 stimulates production of some
cytokines and growth factors while inhibiting others [11–
17,30]. Although IL-4 may be inhibitory to some aspects
of lung inflammation, the presence of IL-4 may be detri-
mental by inducing proliferation of, and collagen produc-
tion by, subsets of lung fibroblasts [31,32]. Further, IL-4 is
a central mediator in the development of asthma [20]. We
detected very low concentrations of IL-4 in only one fifth
of the tracheal aspirates. This suggests that IL-4 does not
play a major role in the lung injury, or protection from
lung injury, associated with BPD. The role of IL-4 later in
the course of the disease was not assessed in this study.
Interleukin-13, which is similar in structure and function
to IL-4, is produced by activated TH2 lymphocytes and
alveolar macrophages [10,33]. Interleukin-13 inhibits
inflammatory cytokine production in macrophages and
epithelial cells and upregulates the anti-inflammatory
cytokine, interleukin-1 receptor antagonist [14]. Thus, IL-
13 potentially moderates lung inflammation. In adult
fibrotic lung diseases significantly increased concentra-
tions of IL-13 can be detected in bronchoalveolar lavage
(BAL) fluid suggesting an up-regulation of this cytokine in
response to lung inflammation [33]. As with IL-4, it has
been shown in animal models that IL-13 protects against
inflammatory lung injury [16]. In contrast, IL-13 was
rarely detected in tracheal aspirates of premature infants
with acute lung injury, and when detected, was well below
physiologic concentrations required for biologic activity.
Table 1: Clinical characteristics of Study Subjects
Characteristic BPD n = 19 no BPD n = 17 p value
Birth weight (grams) 739 ± 27 1052 ± 42 <0.001
Gestation (weeks) 25.3 ± 0.2 27.8 ± 0.5 <0.001
Surfactant therapy 17 (89) 13 (76) 0.296
Ureaplasma isolated 7 (37) 1 (6) 0.026
Mycoplasma isolated 5 (26) 1 (6) 0.100
Chorioamnionitis 1/9 (11) 4/15 (27) 0.430
Antenatal Steroids 9 (53) 10 (53) 0.999
PDA 9 (47) 4 (24) 0.137
Indomethacina 17 (89) 10 (59) 0.034
Days MVb 42 ± 13 7 ± 2 <0.001
Days oxygenb 64 ± 12 11 ± 2 <0.001
Days hospitalb 104 ± 12 69 ± 6 0.009
MV > 28 days 9 (47) 0 <0.01
Pulmonary hemorrhage 6 (32) 0 0.011
Supplemental O2 at 36 weeks PCA 3 (16) 0 0.061
Postnatal steroids 16 (84) 7 (41) 0.005
Age steroids started (days) 8 ± 2 9 ± 2 0.758
IVH 6 (32) 5 (29) 0.888
PVL 3 (16) 1 (6) 0.316
PDA-Patent ductus arteriosus; MV-mechanical ventilation, IVH-Intraventricular hemorrhage; PVL-Periventricular leukomalacia; PCA-
Postconceptional age. aIndomethacin was used prophylactically in most infants. Indomethacin was used to close a clinically significant PDA in 2 
control and 7 BPD infants. bWilcox Rank Sum test was used because data was not normally distributed. Data are presented as Mean ± SEM or as 
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A. Tracheal aspirate concentrations of IL-4 normalized to secretory component in mechanically ventilated very low birth 
weight infants during the first 21 days of life. Number in parenthesis represents the number of TA samples assayed at each time 
point. B. Tracheal aspirate concentrations of IL-4 normalized to secretory component in infants who developed BPD (grey 
bars) and those who did not (black bars) during the first 21 days of life. Concentrations are expressed as pg of cytokine per µg 
secretory component ± SEM. Number in parenthesis represents the number of TA samples assayed at each time point.Page 5 of 8
(page number not for citation purposes)
BMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/8These observations suggest that very premature neonates
may be unable to produce physiologic concentrations of
this cytokine in the lung. This suggests that proinflamma-
tory processes in the lungs of the premature infant may be
relatively unchecked compared to the adult. Thus, as with
IL-4, IL-13 does not appear to have a role in modulating
pulmonary inflammatory responses in preterm infants at
risk of developing BPD.
The mechanisms responsible for the inability of prema-
ture infants to increase concentrations of IL-4 or IL-13 in
response to a significant lung inflammation are unclear. It
could be that the cells that produce these cytokines are not
present in the airways and lungs of the premature new-
born. Alveolar macrophages, one of the cells types that
produce IL-4 are not usually present in the lung at birth in
the absence of congential pneumonia but populate the
lungs shortly after birth. An influx mononuclear cells and
macrophages are part of the inflammatory response that
presages BPD [1]. Thus, it seems likely that the right cell
types are present in the lung after birth. This suggests that
the ability to produce IL-4 or IL-13 in the lung may be
developmentally regulated. Therefore, a functionally
immature lung may lack the ability to produce these
down regulators of inflammation. This may in part
explain the exaggerated inflammatory response frequently
observed in infants who develop BPD. Consistent with
this hypothesis is the report that cord blood mononuclear
cells do not produce significant IL-4 in response to endo-
toxin [34]. Further, we were not able to demonstrate IL-13
production by lipopolysaccharide (LPS) stimulated cord
blood cells (unpublished observations).
The role of airway colonization with Uu in the develop-
ment of chronic lung disease is unclear. Most, but not all
studies, suggest that isolation of Uu from tracheal aspi-
rates is associated with an increased incidence of chronic
lung disease in very low birth weight infants [35–37]. The
frequency of Uu isolation in our infants and the increased
incidence of BPD is in agreement with other reports [35–
37].
Postnatal steroids were used frequently in this study. At
the time when these infants were cared for in our NICU, it
was our practice to treat infants who were ventilator
dependent for more than 7 days with systemic dexameth-
asone. Corticosteroid administration (either antenatal or
postnatal) could potentially inhibit IL-4 production [38].
We did not observe an effect of antenatal or postnatal ster-
oids on IL-4 concentrations. The lack of effect of postnatal
steroids on IL-4 may be due to the time (on average 8
postnatal days) when these were started. At that time IL-4
concentrations were declining.
All studies of this nature suffer from limitations inherent
in their design. Tracheal aspirate cytokine concentrations
may not reflect what is happening at the alveolus or inter-
stitium of the lung. In addition, values of IL-4 or IL-13
normalized to secretory component do not directly esti-
mate the concentration of these compounds in the epithe-
lial lining fluid (ELF) of the lung. In a few samples the raw
concentration of IL-4 was greater than 100 pg/ml. This is
within the range of biological activity of IL-4. IL-4 concen-
trations as low as 10 pg/ml have been reported to cause
partial inhibition of LPS induced IL-8 production in
peripheral blood monocytes in vitro[13]. Thus, it is possi-
ble that biologically significant concentrations of these
cytokines are present in some infants with developing
BPD.
This study examined a relatively small number of tracheal
aspirates in a small number of infants. This sample size
which was sufficient to detect large differences in cytokine
production between BPD and control infants is not suffi-
ciently powered to detect smaller differences [26]. Thus it
is possible that smaller magnitude differences in IL-4 (and
IL-13) do exist between control and BPD infants and
would have been detected with a larger sample. The clini-
cal importance of these small magnitude differences is
uncertain. Additionally, most patients had mild-moderate
BPD and there were few patients who developed severe
BPD. These infants (severe BPD) could have different pat-
terns in IL-4 or IL-13 production that are not obvious in
our study.
In clinical practice infants are extubated as soon as feasi-
ble to limit potential damage from continuing ventila-
tion. Therefore, infants who have less severe lung disease
or recover from their acute lung injury rapidly are not
sampled. Thus, there are disproportionately fewer
samples and fewer time points in infants who recover or
do not develop chronic lung disease. This may introduce
bias into our results limiting the conclusions that may be
drawn. However, we believe that our results are consistent
with other similar clinical studies and in animal models of
lung injury providing further insight into the mechanisms
of chronic lung injury in the newborn.
Conclusions
In summary we have shown that TA concentrations of IL-
4 and IL-13 do not increase significantly during acute lung
injury in premature infants. Further studies are required to
determine the role (if any) of these and other anti-inflam-
matory mediators in the pathogenesis of chronic lung
disease.
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